Loader

Pathways

PathWhiz ID Pathway Meta Data

PW144696

Pw144696 View Pathway
drug action

Mazindol Drug Metabolism Action Pathway

Homo sapiens

PW064691

Pw064691 View Pathway
signaling

MBP

Homo sapiens

PW128003

Pw128003 View Pathway
drug action

Mebendazole Action Pathway

Homo sapiens
Mebendazole is a synthetic benzimidazole anthelmintic used to treat helminth infections. This drug is used for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenal (common hookworm), Necator americanus (American hookworm) infections. Mebendazole causes degenerative alterations in the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP). Due to diminished concentration in ATP, the parasite eventually dies. Mebendazole is administered as an oral tablet.

PW144756

Pw144756 View Pathway
drug action

Mebendazole Drug Metabolism Action Pathway

Homo sapiens

PW146543

Pw146543 View Pathway
drug action

Mebeverine Drug Metabolism Action Pathway

Homo sapiens

PW062003

Pw062003 View Pathway
drug action

Mebhydrolin H1-Antihistamine Action

Homo sapiens
Mebhydrolin is a first-generation H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW146939

Pw146939 View Pathway
drug action

Mebrofenin Drug Metabolism Action Pathway

Homo sapiens

PW176269

Pw176269 View Pathway
metabolic

Mebrofenin Predicted Metabolism Pathway

Homo sapiens
Metabolites of Mebrofenin are predicted with biotransformer.

PW145803

Pw145803 View Pathway
drug action

Mebutamate Drug Metabolism Action Pathway

Homo sapiens

PW132529

Pw132529 View Pathway
metabolic

Mecamylamine Drug Metabolism

Homo sapiens
Mecamylamine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Mecamylamine passes through the liver and is then excreted from the body mainly through the kidney.